Cancer chromosomal instability: therapeutic and diagnostic challenges

Nicholas McGranahan1–3*, Rebecca A. Burrell1*, David Endesfelder1,4, Marco R. Novelli5 & Charles Swanton1, 3+

Introduction

Genomic instability is a striking feature of human cancers [1, 2] that results in genetic aberrations at many levels: from single nucleotide changes at the gene level, gross structural changes at the subchromosomal level to losses and gains of entire chromosomes. Chromosomal instability (CIN) is a form of genomic instability observed in a large proportion of solid tumours and many haematological malignancies. CIN describes a dynamic state in which cells continuously gain or lose whole chromosomes, or parts of chromosomes, at an elevated rate [3], and is therefore a principal mediator of aneuploidy and intra-tumour heterogeneity.

Chromosomal instability (CIN)—which is a high rate of loss or gain of whole or parts of chromosomes—is a characteristic of most human cancers and a cause of tumour aneuploidy and intra-tumour heterogeneity. CIN is associated with poor patient outcome and drug resistance, which could be mediated by evolutionary adaptation fostered by intra-tumour heterogeneity. In this review, we discuss the clinical consequences of CIN and the challenges inherent to its measurement in tumour specimens. The relationship between CIN and prognosis supports assessment of CIN status in the clinical setting and suggests that stratifying tumours according to levels of CIN could facilitate clinical risk assessment.

Keywords: cancer; chromosomal instability; genomic instability; aneuploidy; intra-tumour heterogeneity

In this review, we outline the mechanisms that might contribute to CIN and discuss the clinical, pathological and molecular evidence that supports the need for assessment of CIN status in the clinical setting. We discuss the impact of CIN on patient outcome and highlight the challenges associated with determining CIN status in the clinical setting.

Classification of CIN

CIN tumour cells usually contain both numerical and structural chromosome changes (Fig 1; [10]). Numerical CIN (nCIN) refers to gain or loss of whole chromosomes at notably higher rates than normal cells. Structural CIN (sCIN), on the other hand, refers to an increased rate of formation of structurally abnormal chromosomes,
resulting in gain or loss of chromosome fragments, translocations, deletions and amplifications of DNA [11]. Individual chromosomes in CIN cancer genomes are often aberrant at both the whole and sub-chromosomal level ([12], see also Reviews by Holland & Cleveland and Pau & Amon in this issue).

CIN is thought to be a principal cause of aneuploidy, a state of abnormal chromosomal number [13]. Aneuploidy, however, is not synonymous with CIN; whilst CIN always results in aneuploidy, aneuploidy is not always associated with CIN. In human cancers, this is exemplified by hyperdiploid acute lymphoblastic leukaemia and near-triploid neuroblastoma, which have a stable aneuploid karyotype and a favourable prognosis [14,15]. The distinction between CIN and aneuploidy is important particularly when developing methods to measure CIN that must capture its dynamic nature (see CIN—diagnostic methods below), and also when exploring its impact on prognosis (see Clinical impact of CIN below). The distinction is also important when considering mechanisms that lead to CIN, which must consider both the structural and numerical chromosome aberrations observed in CIN cells.

Efforts to understand nCIN have focused on elucidating the mechanisms that lead to mitotic errors and the uneven distribution of chromosomes between daughter cells (Fig 2A,B). Chromosomally stable cells rarely undergo chromosome missegregation events (only in approximately 1% of cell divisions [16]), in contrast to CIN cancer cells, in which chromosomes missegregate in excess of every fifth division [16,17]. Putative mechanisms that might contribute to nCIN include weakening of the mitotic checkpoint (Fig 2B; [18–21]); aberrant sister chromatid cohesion (Fig 2C; [22–25]); centrosome amplification (Fig 2D; [26]) and improper attachment of chromosomes to the mitotic spindle (Fig 2E; [27,28]). Recent evidence has linked whole-chromosome missegregation in mitosis to DNA damage and structural aberrations in the subsequent interphase [29,30]. These mechanisms are discussed in detail in the Reviews by Holland & Cleveland and Pau & Amon in this issue of EMBO reports.

CIN genomes are characterized by many forms of structural genomic aberration, including reciprocal and non-reciprocal translocations, amplifications, insertions and deletions [31]. A key structural feature associated with sCIN is the formation of ‘reactive’ chromosomes after chromosome breaks. These ‘reactive’ chromosomes can result in breakage–fusion–bridge cycles (BFB), which propagate extensive genomic rearrangements (see [32] for a review). BFB cycles have been linked to sCIN and associated with intra-tumour heterogeneity [11,33], and can lead to whole-chromosome missegregation [34,35]. Accordingly, there is a need to understand the mechanisms by which BFB cycles can be initiated. Three main explanations have been offered to account for the formation of breaks in chromosomes: telomere dysfunction [34,36–38], fragile sites [39,40] and aberrant DNA repair pathways [31,41].

Taken together, the studies of both nCIN and sCIN highlight the diversity and complexity of the mechanisms that contribute to CIN, and hint at the multitude of genetic alterations that could be responsible for these phenotypes, even within one individual tumour [42,43]. Further work will be needed to analyse which mechanisms are the most frequent, which mechanisms occur in vivo and whether distinct mechanisms interact. A significant correlation has been found between nCIN and sCIN in human cancer cell lines derived from a range of tissues [44], and recent studies have revealed that these two forms of CIN might be generated by common mechanisms [29,30,35,45]. A reductionist view of CIN—whereby numerical and structural CIN are considered in isolation—is therefore probably incomplete (Sidebar A).

### CIN—diagnostic methods

The CIN status of tumour specimens is not routinely assessed in the clinical setting. Although existing parameters, such as tumour grade, often correlate with CIN [46,47], these are not direct measures of genomic instability. Ultimately, a direct measurement of CIN requires the determination of cell-to-cell variability in chromosome number and structure within a tumour cell population, as well as an assessment of the rate at which these chromosomal changes occur. Broadly speaking, diagnostic methods can be divided according to whether they directly or indirectly measure levels of CIN. Indirect methods rely on proxies for CIN. These can be further sub-classified according to whether they measure intra-tumour heterogeneity and unstable aneuploidy, or karyotypic complexity, on the basis of the average numerical or structural chromosomal changes across the cell population of the tumour. As these methods have been evaluated in retrospective studies, there remains a need for prospective validation of methods to identify CIN in tumours.

**Direct approaches for measuring CIN.** Due to its dynamic nature, direct methods for determining CIN from fixed tumour tissue are limited to the assessment of the frequency of anaphase segregation errors. This method therefore captures the dynamic nature of CIN and has been used to assess CIN status in diffuse large B-cell lymphoma specimens [48]. However, this approach might be challenging in tumours with lower proliferation indexes and in tumours with morphology unsuited to scoring anaphases.

**Intra-tumour heterogeneity measures of CIN.** An alternative method for assessing CIN from tumour specimens involves measuring the level of cell-to-cell variability in chromosome number and structure.

### Glossary

- **17-AAG**: 17-N-allylamo-17-demethoxygeldanamycin
- **AURKA/B**: aurora kinase A/B
- **AMPK**: 5' adenosine monophosphate-activated protein kinase
- **AICAR**: 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide
- **BUB1B**: budding uninhibited by benzimidazoles 1 homologue beta (yeast)
- **CCNB1/B2**: cyclin B1/2
- **CDC20**: cell division cycle 20 homologue (yeast)
- **CENP-E**: centromere linked motor protein E
- **H2AFX**: H2A histone family, member X
- **HER2**: human epidermal growth factor receptor 2
- **HSP90**: heat shock protein 90
- **MPF**: monopolar spindle 1-like
- **NEK2**: NIMA (never in mitosis gene a)-related kinase 2
- **qPCR**: quantitative PCR
- **ZWINT**: ZW10 interactor

### Sidebar A | In need of answers

1. **What are the main molecular mechanisms that generate CIN in cancer?**
2. **Can structural and numerical CIN be considered in isolation, or are they governed by unified mechanisms?**
3. **What is the best method to measure CIN in tumour specimens?**
4. **Can CIN status be used in the clinic for risk-stratification purposes?**
5. **Can we exploit CIN as a therapeutic target?**
In this manner, one can quantify both aneuploidy and intra-tumour heterogeneity simultaneously and thereby infer CIN status. Such methods can distinguish between stable and unstable aneuploidy, the latter of which equates to CIN.

FISH has been adopted as one of the main methods for the assessment of CIN status in tumours (Fig 3A). Variations in chromosome copy number across the cell population can be quantified using fluorescently labelled DNA probes that bind to the centromeres of specific chromosomes [49]. FISH thus allows the assessment of the chromosomal status of hundreds of cells, and the rate of change can be inferred from the cell-to-cell variability in chromosome number [3]. The usefulness of FISH in assessing CIN status has been demonstrated in several retrospective studies, including of breast, lung and oral cancer (see Table 1 and The clinical impact has been demonstrated in several retrospective studies, including

Table 1: Clinical relevance of CIN

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Method of measuring CIN</th>
<th>Associated outcomes</th>
<th>Additional details</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung cancer (NSCLC)</td>
<td>FISH (n = 63)</td>
<td>Poor prognosis (OS and DFS)</td>
<td>Korean patients</td>
<td>Choi et al [4]</td>
</tr>
<tr>
<td></td>
<td>FISH (n = 47)</td>
<td>Poor prognosis (OS)</td>
<td>Korean patients</td>
<td>Yoo et al [51]</td>
</tr>
<tr>
<td></td>
<td>FISH (n = 50)</td>
<td>Poor prognosis (OS)</td>
<td></td>
<td>Nakamura et al [52]</td>
</tr>
<tr>
<td>12-gene signature (n = 647)</td>
<td>Poor prognosis (OS)</td>
<td>Multiple datasets</td>
<td></td>
<td>Mettu et al [66]</td>
</tr>
<tr>
<td>CIN70 signature (n = 62)</td>
<td>Poor clinical outcome</td>
<td></td>
<td></td>
<td>Carter et al [5]</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>SSI (n = 890)</td>
<td>Poor prognosis (OS)</td>
<td>CIN measured within diploid, tetraploid and aneuploid classified tumours</td>
<td>Kronenwett et al [55]</td>
</tr>
<tr>
<td></td>
<td>SNP (n = 313)</td>
<td>Poor prognosis (MFS)</td>
<td>Significant in ER-positive, luminal B and HER2-positive subtypes (not in ER-negative patients)</td>
<td>Smid et al [46]</td>
</tr>
<tr>
<td>12-gene signature (n = 469)</td>
<td>Poor prognosis (DFS and RFS)</td>
<td>Multiple datasets</td>
<td></td>
<td>Habermann et al [9]</td>
</tr>
<tr>
<td>CIN70 signature (n = 1866)</td>
<td>Poor clinical outcome</td>
<td>Multiple datasets</td>
<td></td>
<td>Carter et al [5]</td>
</tr>
<tr>
<td></td>
<td>FISH (n = 31)</td>
<td>Lymph node metastasis</td>
<td></td>
<td>Takami et al [50]</td>
</tr>
<tr>
<td>Myelodysplastic syndrome</td>
<td>FISH (n = 65)</td>
<td>Poor prognosis (DFS)</td>
<td></td>
<td>Heilig et al [102]</td>
</tr>
<tr>
<td>Endocrine pancreatic tumours</td>
<td>CGH (n = 62)</td>
<td>Metastasis</td>
<td></td>
<td>Jonkers et al [79]</td>
</tr>
<tr>
<td>Colon cancer</td>
<td>12-gene signature (n = 92)</td>
<td>Recurrence of colon cancer</td>
<td>Multiple datasets</td>
<td>Walton et al [6]</td>
</tr>
<tr>
<td></td>
<td>Flow cytometry/image</td>
<td>Poor prognosis</td>
<td>Meta-analysis</td>
<td>Walther et al [6]</td>
</tr>
<tr>
<td></td>
<td>cytometry (n = 10126)</td>
<td></td>
<td></td>
<td>Mettu et al [66]</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>12-gene signature (n = 124)</td>
<td>Poor prognosis (RFS)</td>
<td></td>
<td>Murayama-Hosokawa et al [70]</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>SNP (n = 31)</td>
<td>Poor prognosis (OS)</td>
<td></td>
<td>Nakagawa et al [71]</td>
</tr>
<tr>
<td>Synovial sarcoma</td>
<td>CGH (n = 22)</td>
<td>Poor prognosis (OS)</td>
<td></td>
<td>Sato et al [53]</td>
</tr>
<tr>
<td>Oral cancer (SCCs)</td>
<td>FISH (n = 77)</td>
<td>Poor prognosis (OS and DFS)</td>
<td></td>
<td>Bergshoeff et al [103]</td>
</tr>
<tr>
<td></td>
<td>FISH (n = 20)</td>
<td>(Loco) regional tumour outgrowth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse large B-cell lymphoma</td>
<td>Anaphase segregation errors (n = 54)</td>
<td>Poor prognosis (RFS)</td>
<td></td>
<td>Bakhoum et al [48]</td>
</tr>
</tbody>
</table>

CGH, comparative genome hybridization; DFS, disease-free survival; ER, oestrogen receptor; FISH, fluorescence in situ hybridization; MFS, metastasis-free survival; NSCLC, non-small-cell lung cancer; OS, overall survival; RFS, relapse-free survival; SCC, squamous cell carcinoma; SNP, single-nucleotide polymorphism; SSI, stem line scatter index.

In this manner, one can quantify both aneuploidy and intra-tumour heterogeneity simultaneously and thereby infer CIN status. Such methods can distinguish between stable and unstable aneuploidy, the latter of which equates to CIN.

FISH has been adopted as one of the main methods for the assessment of CIN status in tumours (Fig 3A). Variations in chromosome copy number across the cell population can be quantified using fluorescently labelled DNA probes that bind to the centromeres of specific chromosomes [49]. FISH thus allows the assessment of the chromosomal status of hundreds of cells, and the rate of change can be inferred from the cell-to-cell variability in chromosome number [3]. The usefulness of FISH in assessing CIN status has been demonstrated in several retrospective studies, including of breast, lung and oral cancer (see Table 1 and The clinical impact has been demonstrated in several retrospective studies, including

Table 1: Clinical relevance of CIN

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Method of measuring CIN</th>
<th>Associated outcomes</th>
<th>Additional details</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung cancer (NSCLC)</td>
<td>FISH (n = 63)</td>
<td>Poor prognosis (OS and DFS)</td>
<td>Korean patients</td>
<td>Choi et al [4]</td>
</tr>
<tr>
<td></td>
<td>FISH (n = 47)</td>
<td>Poor prognosis (OS)</td>
<td>Korean patients</td>
<td>Yoo et al [51]</td>
</tr>
<tr>
<td></td>
<td>FISH (n = 50)</td>
<td>Poor prognosis (OS)</td>
<td></td>
<td>Nakamura et al [52]</td>
</tr>
<tr>
<td>12-gene signature (n = 647)</td>
<td>Poor prognosis (OS)</td>
<td>Multiple datasets</td>
<td></td>
<td>Mettu et al [66]</td>
</tr>
<tr>
<td>CIN70 signature (n = 62)</td>
<td>Poor clinical outcome</td>
<td></td>
<td></td>
<td>Carter et al [5]</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>SSI (n = 890)</td>
<td>Poor prognosis (OS)</td>
<td>CIN measured within diploid, tetraploid and aneuploid classified tumours</td>
<td>Kronenwett et al [55]</td>
</tr>
<tr>
<td></td>
<td>SNP (n = 313)</td>
<td>Poor prognosis (MFS)</td>
<td>Significant in ER-positive, luminal B and HER2-positive subtypes (not in ER-negative patients)</td>
<td>Smid et al [46]</td>
</tr>
<tr>
<td>12-gene signature (n = 469)</td>
<td>Poor prognosis (DFS and RFS)</td>
<td>Multiple datasets</td>
<td></td>
<td>Habermann et al [9]</td>
</tr>
<tr>
<td>CIN70 signature (n = 1866)</td>
<td>Poor clinical outcome</td>
<td>Multiple datasets</td>
<td></td>
<td>Carter et al [5]</td>
</tr>
<tr>
<td></td>
<td>FISH (n = 31)</td>
<td>Lymph node metastasis</td>
<td></td>
<td>Takami et al [50]</td>
</tr>
<tr>
<td>Myelodysplastic syndrome</td>
<td>FISH (n = 65)</td>
<td>Poor prognosis (DFS)</td>
<td></td>
<td>Heilig et al [102]</td>
</tr>
<tr>
<td>Endocrine pancreatic tumours</td>
<td>CGH (n = 62)</td>
<td>Metastasis</td>
<td></td>
<td>Jonkers et al [79]</td>
</tr>
<tr>
<td>Colon cancer</td>
<td>12-gene signature (n = 92)</td>
<td>Recurrence of colon cancer</td>
<td>Multiple datasets</td>
<td>Walton et al [6]</td>
</tr>
<tr>
<td></td>
<td>Flow cytometry/image</td>
<td>Poor prognosis</td>
<td>Meta-analysis</td>
<td>Walther et al [6]</td>
</tr>
<tr>
<td></td>
<td>cytometry (n = 10126)</td>
<td></td>
<td></td>
<td>Mettu et al [66]</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>12-gene signature (n = 124)</td>
<td>Poor prognosis (RFS)</td>
<td></td>
<td>Murayama-Hosokawa et al [70]</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>SNP (n = 31)</td>
<td>Poor prognosis (OS)</td>
<td></td>
<td>Nakagawa et al [71]</td>
</tr>
<tr>
<td>Synovial sarcoma</td>
<td>CGH (n = 22)</td>
<td>Poor prognosis (OS)</td>
<td></td>
<td>Sato et al [53]</td>
</tr>
<tr>
<td>Oral cancer (SCCs)</td>
<td>FISH (n = 77)</td>
<td>Poor prognosis (OS and DFS)</td>
<td></td>
<td>Bergshoeff et al [103]</td>
</tr>
<tr>
<td></td>
<td>FISH (n = 20)</td>
<td>(Loco) regional tumour outgrowth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse large B-cell lymphoma</td>
<td>Anaphase segregation errors (n = 54)</td>
<td>Poor prognosis (RFS)</td>
<td></td>
<td>Bakhoum et al [48]</td>
</tr>
</tbody>
</table>

CGH, comparative genome hybridization; DFS, disease-free survival; ER, oestrogen receptor; FISH, fluorescence in situ hybridization; MFS, metastasis-free survival; NSCLC, non-small-cell lung cancer; OS, overall survival; RFS, relapse-free survival; SCC, squamous cell carcinoma; SNP, single-nucleotide polymorphism; SSI, stem line scatter index.
Cytometry provides an overview of cellular DNA content, it has predominantly been used for identification of tumour aneuploidy and polyploidy rather than CIN (Fig 3B,C). Furthermore, its accuracy can be affected by a variety of factors, including section thickness and tissue preservation.

New technologies will probably arise in the future for the determination of CIN status. Single-cell, comparative genomic hybridization (CGH) [56] can yield information on both numerical and structural chromosomal aberrations at a single-cell level, and heterogeneity can then be quantified by comparing multiple cells. CGH, however, cannot readily detect structural rearrangements that do not involve genomic imbalances, such as balanced chromosome inversions or translocations. In addition, single-cell CGH is not amenable to high-throughput analysis and its cost is substantial. A more detailed picture of the genomic landscape can be obtained through next-generation sequencing systems, which adopt massively parallel sequencing techniques. Single-nucleus sequencing—which combines flow sorting with whole-genome amplification and next-generation sequencing—has been recently used to quantify genomic copy number profiles of individual tumour cells at a high resolution (50 kb) [57]. A comparison of the profiles of multiple cells allows inference of the levels of intra-tumour heterogeneity. It seems probable that such single-cell, next-generation sequencing approaches to define tumour CIN status will become more prevalent as costs decrease and technology improves.

**Multi-cell, population-based measures of CIN.** Karyotypic complexity measures of CIN are generally performed on an aggregated population of cells. Therefore, these techniques provide a static picture of chromosome complexity or of a CIN-associated gene-expression signature, yielding limited direct evidence of cell-to-cell heterogeneity or rates of structural or numerical chromosomal change.

Conventional array CGH makes use of DNA from multiple cells, and can be used to define the structural chromosomal complexity and copy number changes of a tumour sample [58]. More recently, high-density, single-nucleotide polymorphism (SNP) microarrays have been used to define genome-wide copy number changes. This technique provides superior resolution to conventional array-based methods, and has the advantage of being able to detect loss of heterozygosity (LOH) events, including copy-neutral LOH [59]. Quantifying the proportion of the genome that shows copy number aberrations has allowed the definition of genome integrity indexes [60] and CIN scores [46, 61] that have prognostic value. An advantage of these indexes is their ability to capture both numerical and structural chromosome complexity, which is difficult to achieve using the more direct CIN-detection methods described above.

SNP microarray analysis can also be complemented by massively parallel paired-end sequencing of rearrangements, which provides a more complete, higher resolution picture of cancer-specific genome aberrations [62]. By using such an approach, a striking new mechanism for genomic instability—termed chromothripsis—has been recently uncovered [59], whereby a chromosome undergoes tens to hundreds of rearrangements in a single cellular event. Furthermore, the degree of heterogeneity can be estimated by using next-generation sequencing data through the detection of low frequency mutations, which are indicative of sub-clonal architecture [63,64]. However, whether these mutations arise through CIN remains unclear. Given the burgeoning data from next-generation sequencing technologies, it will become increasingly important to establish new methods that use next-generation sequencing datasets to assess the levels of intra-tumour heterogeneity and CIN. A recent study by
Fig 2 | Mechanisms of chromosome missegregation in mitosis. (A) A wild-type division, producing identical daughter cells. (B–E) Mitotic errors that result in aneuploid daughter cells.
our group [64] used multi-region, next-generation sequencing to sequence multiple spatially separated regions from individual clear-cell renal tumours. This uncovered branched evolutionary tumour growth and striking mutational intra-tumour heterogeneity, coupled with tumour aneuploidy and karyotypic complexity that was heterogeneous between distinct biopsies.

An appreciation of the inherent heterogeneity in cancer has led to the development of gene-expression-based approaches that might reflect CIN status. A summary of the total level of chromosomal aberrations in a given tumour at the transcriptional level, total functional aneuploidy (tFA), has been used to measure chromosomal imbalance [5]. By correlating this proxy of aneuploidy with expression measures, a set of 70 CIN genes that consistently correlated with tFA across several cancer types was identified. The value of the CIN70 signature as a proxy for CIN has since been further validated, as it correlates with both structural complexity (defined from SNP microarrays) and numerical CIN (defined by DNA image cytometry) [61]. Interestingly, among the 70 genes in the list were several key regulators that facilitate the maintenance of faithful replication and segregation of chromosomes, including AURKB, AURKA, NEK2, H2AFX, CDC20, ZWINT, CCNB1 and CCNB2. The prognostic ability of the CIN70 signature is probably not only based on its detection of proliferation rate; when genes defined as cell-cycle-regulated were not included in the signature, it still had prognostic ability.

A 12-gene expression signature associated with genomic instability in breast cancer has been recently defined; the signature was derived by identifying a set of 12 genes whose expression can discriminate between stable and unstable aneuploidy (defined by DNA image cytometry) in a cohort of 48 breast cancer specimens [9,55]. The biological and prognostic value of this gene expression signature has been demonstrated across a range of cancer types [9,66]. Interestingly, MammaPrint® and Oncotype DX®—two clinically used breast cancer prognostic gene expression signatures—reflect genomic instability levels as measured by the 12-gene signature [9]. There is no overlap between the genes in the CIN70 signature and the 12-gene signature. However, the expression of the signatures are highly correlated [47], and AURKA—a gene identified in the CIN70 signature and previously linked to aneuploidy [67]—has significantly increased expression in the genomically unstable tumours as defined by the 12-gene genomic instability signature [9].

Conceivably, high-throughput qPCR-based approaches could be derived from such CIN expression signatures. Such approaches might be applicable to the analysis of paraffin-embedded material, to rapidly estimate CIN status of clinical samples. Although the dynamic nature of CIN cannot be fully captured by multi-cell, population-based approaches, these techniques can facilitate studies exploring the genetic and molecular changes underlying CIN. Furthermore, given the correlation of gene expression signatures and copy-number-based scores with direct measures of CIN [61], these could be used to facilitate the assessment of the clinical consequences of CIN in a higher throughput and less labour-intensive manner than FISH-based approaches.

**Consequences of CIN**

CIN has profound effects on the genome of a cell. Structural rearrangements can result in distinct molecular genetic alterations, such as the formation of fusion gene products, the amplification of some genes and the deletion of others [31]. The repercussions of numerical
chromosome changes include alterations to gene dosage and LOH events [68]. Tumour chromosomal instability would be therefore expected to be directly associated with patient prognosis.

The clinical impact of CIN. The relationship between CIN and cancer prognosis has been explored across a range of cancer types, using various methods. In several retrospective studies, summarized in Table 1, CIN has been consistently associated with poor prognosis, providing additional prognostic information beyond conventional clinical parameters such as tumour grade.

In non-small-cell lung cancer (NSCLC), CIN is related to unfavourable prognosis [4,5,51,52]. In three separate studies, all using FISH to measure CIN, the association between CIN status and overall survival was shown to be significant, independent of conventional risk factors such as tumour stage, age and sex in multivariate analyses [4,51,52]. The association between CIN and poor prognosis in lung cancer was also found to hold when using gene expression signatures to assess CIN status [5,66].

In a meta-analysis of 10,126 colon cancer patients, tumour aneuploidy was used as a surrogate measure for CIN and found to be associated with a worse prognosis, either in terms of overall survival or, if not available, progression-free survival [6]. Aneuploidy status—quantified by either flow cytometry (9,526 patients) or image cytometry (600 patients)—could stratify colon cancer patients independently of standard pathological staging, and irrespective of ethnic background, anatomical location and treatment with 5-fluourouracil (5-FU)-based adjuvant chemotherapy. By using a 12-gene genomic instability signature, CIN predicted colon cancer recurrence independently of tumour stage [66].

In breast cancer, CIN has been quantified by using FISH and DNA image cytometry techniques, as well as summary gene expression and SNP-array methods. By using the SSI as a means to assess CIN (see Intra-tumour heterogeneity measures of CIN), CIN was linked to a worse prognosis, in terms of cancer-specific survival [55]. CIN status provided additional information to the ploidy status of a tumour, emphasizing the need to distinguish between aneuploidy or polyploidy and CIN when considering CIN assessment in clinical samples. FISH-based measures have found CIN to be associated with lymph node metastasis and prevalence of oestrogen receptor (ER) negativity [50,69]. SNP-based measures of chromosomal aberrations are associated with more aggressive subgroups of breast cancer—such as ER-negative and triple-negative [46]. Interestingly, CIN scores are prognostic in certain subgroups (ER-positive, luminal B and HER2), but not others (ER-negative), suggesting a complex relationship between CIN and outcome in breast cancer.

Furthermore, studies in ovarian, endometrial, synovial and oral cancers, as well as diffuse B-cell lymphoma, have suggested that CIN is associated with poor prognosis [48,53,66,70,71]. Overall, these studies associate CIN and poor prognosis across a range of cancer types, and highlight the relationship between CIN and multiple clinical parameters, including the probability of disease recurrence. However, it is important to emphasize that the studies have used different techniques for the measurement of CIN; in particular, some studies have used surrogates for CIN, such as aneuploidy status, whereas others have measured CIN more directly. Indirect measures of CIN increase the probability of confounding variables and could mask more subtle relationships between CIN and prognosis. Indeed, given that CIN probably has negative effects on cellular fitness, its impact on prognosis is probably not straightforward, as will be discussed further below (see Exploiting CIN in the clinical setting).

A darwinian perspective on the clinical impact of CIN. The mechanisms by which CIN contributes to cancer outcome can be considered from a darwinian point of view. Selection depends on cell-to-cell phenotypic variation. CIN is characterized by gain and loss of chromosomes or parts of chromosomes, which gives rise to genetic variation, and thus generates distinct cellular phenotypes. This intra-tumour heterogeneity could facilitate darwinian selection, thereby providing a means for the tumour to adapt to environmental and stromal pressures [7,72]. Consistent with this hypothesis, findings in mouse models suggest that CIN might promote early tumour relapse [73] and studies in yeast have found aneuploidy can generate important phenotypic variation that might lead to fitness gains under stressful conditions [74]. Furthermore, evolutionary models posit that CIN might be selected for by increasing the rate at which tumour suppressor genes are lost from the genome [75].

Given the heterogeneity that arises as a consequence of CIN, and the propensity for selection and adaptation, it seems probable that the relationship of elevated levels of CIN and poor prognosis could ultimately be explained by the emergence of drug resistance [8,76–78] and an increased capacity to metastasize to distant sites [50,79]. Consistent with this explanation, CIN cancer cell lines acquire multi-drug resistance at an elevated rate compared with chromosomally stable, diploid cells [77].

Furthermore, CIN has also been shown to be associated with intrinsic taxane resistance in ovarian cancer patients and cancer cell lines [76]. More recently, we have found that CIN is associated with intrinsic multi-drug resistance in colorectal cancer: CIN cells are intrinsically multi-drug resistant compared with diploid cell lines, independent of somatic mutation status—according to the mutation status of 20 recurrently mutated genes assessed in colorectal cancer—and proliferation rate [8]. A meta-analysis of tumour drug response in colorectal cancer also supported a relationship between tumour CIN status and drug resistance [8].

From a darwinian perspective, a drug treatment might be viewed as a selective pressure. Increased heterogeneity resulting from CIN could increase the probability of resistant sub-clones arising in the tumour before drug therapy. The emergence of drug-resistant disease in this case might be a direct consequence of tumour heterogeneity resulting from CIN. An alternative, but not mutually exclusive explanation based on the ability of CIN tumours to survive the impact of repeated extensive genome remodelling, is the existence of a CIN survival phenotype [43]. This survival phenotype is postulated to reflect an adaptation to CIN, which could also
facilitate intrinsic drug resistance. According to this hypothesis, intrinsic drug resistance could be a feature of cells with elevated levels of CIN, as opposed to being purely a consequence of the intra-tumour heterogeneity promoted by CIN.

Taken together, these studies suggest CIN could have a central role in determining patient outcome: increased levels of CIN might facilitate darwinian adaptation and selection, thus having a negative impact on patient outcome. This association highlights the clinical relevance of CIN in cancers and suggests CIN status could be exploited in the clinical setting.

**Exploiting CIN in the clinical setting**

Given the prevalence and prognostic impact of CIN in human cancers, there is a clinical need to exploit tumour CIN status. CIN status could be used to assist prognostic predictions and could be a therapeutic target.

*CIN as a prognostic tool.* The development of robust clinical tools to assess CIN status could assist in risk stratification. However, as has been discussed, there are multiple possible tests to measure CIN, each with its own advantages and disadvantages. Thus, a central goal will be to determine which test most accurately determines CIN status of tumour specimens in prospective studies, whilst balancing practical and economic considerations. Different tests might perform better in different cancer types. Furthermore, given the potential variability in the degree of CIN, a clinically relevant test must include defined thresholds that allow the oncologist to distinguish between patients who have good or poor prognoses. Defining thresholds to identify CIN tumours will be challenging, particularly as the relationship between CIN and prognosis is probably complex.

Crucially, a threshold for CIN must balance the clinically important concept that it might have negative effects on tumour fitness with its potential to enhance tumour growth. Experimental studies in yeast and murine systems have demonstrated that an abnormal chromosomal number can be deleterious to normal cells, negatively affecting proliferation [80,81]. It remains unclear, however, whether the growth of aneuploid tumour cells is hindered in a similar manner, or whether this has been overcome during tumorigenesis. A recent study suggested that chromosome gains and losses might serve to redress imbalances in the stoichiometry of protein complexes, which can result from aneuploidy [82], raising the possibility that CIN might enable cells to overcome the negative effects of aneuploidy. However, in addition to the potential negative effects of having an abnormal chromosome complement, CIN cells probably accumulate deleterious genomic events fostered by continuing gross numerical or structural chromosomal changes, occurring from one cell division to the next [83]. It has thus been suggested that there is an optimal level of CIN in tumours required for tumour adaptation and progression, beyond which CIN becomes unfavourable [7,84]. Such a scenario, whereby extreme CIN is deleterious for a tumour, might be comparable to ‘mutational meltdown’ in bacteria [85], or error catastrophe in viruses [86].

Evidence substantiating the idea that excessive levels of CIN might have adverse consequences for a tumour derives from mouse models and studies on human cancer cell lines. Mice with reduced levels of CENP-E have CIN and develop tumours [13]. However, intriguingly, CENP-E-induced CIN was found to have tumour-suppressive abilities in some contexts—in tissues that had a pre-existing level of aneuploidy, which was increased through depletion of CENP-E. This suggests that excessive CIN might be disadvantageous for a tumour. Consistent with this observation, excessive CIN, introduced by inactivation of spindle assembly checkpoint components, leads to excessive aneuploidy and cell death in human cancer cells [87], and multipolar cell divisions generate highly aneuploid, non-viable cells [26].

Further supporting this hypothesis, a recent retrospective study has suggested a nonlinear relationship between CIN and cancer outcome [61]. Specifically, in a cohort of 265 patients with ER-negative breast cancers, extreme CIN—defined as tumours in the upper quartile of CIN70 [5] expression—was associated with a significantly better prognosis, in terms of recurrence-free or distant metastasis-free survival, compared with patients having tumours in the third CIN70 expression quartile. The association between extreme CIN and improved prognosis was also observed in ovarian, gastric and non-small-cell lung cancers, but not in ER-positive breast cancers. These findings have been further validated in a study of ER-negative breast cancers, in which CIN was assessed by dual centromeric FISH analysis [88]. This paradoxical observation indicates that the relationship between CIN and prognosis is probably complex. Hence, defining thresholds of CIN that are associated with poor or, conversely, improved prognosis, might be challenging. Furthermore, it suggests that the relationship of CIN with prognosis might vary between tumour types and subgroups. It is interesting to note that measuring aneuploidy alone would probably not have detected this relationship, emphasizing that CIN status can provide further prognostic information. Nevertheless, despite this intriguing association, these data are derived from small retrospective analyses, and validation in larger cohorts using pre-defined CIN thresholds is required before such observations are suitable for clinical implementation.

*CIN as a therapeutic target.* Drug resistance and poor prognosis associated with CIN tumours renders their treatment a considerable challenge. However, the frequency and clinical significance of CIN and its restriction to neoplastic tissue suggests the CIN phenotype could be an attractive therapeutic target [89]. In this regard, the direct targeting of CIN by anti-cancer therapeutics is a subject of active research [90–92].

Given the plethora of mechanisms that have been attributed to CIN, several possible strategies have been suggested. For example, supernumerary centrosomes observed in CIN cells could be targetable by a drug that impedes centrosome clustering and enforces lethal multipolar cell divisions [93]. Observations that extreme CIN might be detrimental for cancer growth suggest potential therapeutic approaches. To this end, tumour cells can be selectively killed by the anti-mitotic drug paclitaxel if levels of the essential mitotic regulators MPS1 and BUB1B are first reduced, inducing excessive chromosome missegregation [94].

In addition, studies in cancer cell lines and yeast have indicated that there could be targetable cellular adaptations to the aneuploid and CIN state [16,80,95–97]. The NCI-60 drug discovery panel of human cancer cell lines was analysed to uncover potential anticancer agents that specifically target CIN cancer cells [91,98]. Seven groups of compounds that could preferentially target unstable cell lines through growth inhibition were uncovered by using this approach, and further studies are warranted to examine the activity of these compounds. A recent study identified three energy and proteotoxic stress-inducing compounds—AICAR, 17-AAG and chloroquine—that...
showed selectivity against aneuploid primary mouse embryonic fibroblasts carrying Robertsonian fusion chromosomes [99]. Of these, AICAR (AMPK activator) and 17-AAG (HSP90 inhibitor) could also target human aneuploid cancer cells. Interestingly, it has been shown recently that inhibition of HSP90 in yeast induces CIN and aneuploidy [100]. It is tempting to speculate, on the basis of these observations, that HSP90 inhibition might induce excessive CIN, resulting in cell lethality in cells with a pre-existing level of aneuploidy or CIN, similar to previous findings [94]. These results emphasize that further work is warranted to assess the efficacy of these drugs against aneuploid cells, and to understand the precise relationship between these compounds and protein overload [101]. However, it is unclear whether targeting aneuploidy will be sufficient to target CIN cells, as these cells must tolerate ongoing structural and numerical chromosome aberrations. Efforts to identify mechanisms of CIN tolerance need to consider both ongoing structural and numerical chromosome aberrations observed in CIN genomes.

Conclusion
A significant obstacle to the exploitation of CIN in the clinical setting results from our limited understanding of the mechanisms by which this form of genomic instability is driven. The molecular mechanisms that contribute to structural and numerical aberrations in CIN tumours have proved elusive. This problem has been compounded by a lack of understanding as to whether structural and numerical changes are initiated by unifying mechanisms. Further research is needed to elucidate crucial drivers and suppressors of CIN, and to explore whether subtypes of CIN with distinct patterns of chromosomal aberrations exist across cancer types.

The relationship between CIN and prognosis is evidently complex; CIN has been associated with adverse patient survival and linked with both intrinsic and acquired drug resistance. By contrast, emerging evidence suggests that extreme CIN might be associated with improved patient outcome. Such a paradoxical relationship between CIN status and clinical outcome creates a challenge both for the targeting of this pattern of genome instability, and in defining CIN thresholds to predict prognosis. A key impediment to the implementation of CIN assessment in the clinical setting remains the technical difficulty associated with its measurement. Improvements in clinicopathological methods to identify CIN tumours are essential, alongside efforts to target this pattern of genomic instability. CIN-specific drug discovery approaches developed in parallel with CIN-stratification criteria will be crucial to improve patient survival outcome in this high-risk disease cohort.

ACKNOWLEDGEMENTS
C.S. is funded by Cancer Research UK and the Medical Research Council and is an MRC Senior Research Fellow.

CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.

REFERENCES
CIN—a clinical challenge


